Biography:
Kizito Kyeremateng, BSc, PharmD, is a Director of Medical Affairs in Dermatology with extensive experience in pharmaceutical medical affairs. He leads medical strategy at Sun Pharma, advancing evidence-based approaches to acne, alopecia areata, and other skin diseases. His research includes peer-reviewed publications on acne, clascoterone, alopecia areata, and deuruxolitinib, contributing to the understanding of disease pathophysiology and treatment. Dr. Kyeremateng earned his PharmD from Idaho State University and remains actively engaged in clinical research, scientific publications, and medical communications.
Title : Efficacy of deuruxolitinib in patients with severe alopecia areata by baseline nail involvement: Pooled post hoc analysis of the THRIVE-AA1 and THRIVE-AA2 phase 3 trials
Title : Maintenance of hair regrowth following dose reduction or discontinuation of deuruxolitinib in patients with severe alopecia areata: A phase 2 randomized study